A reply to ‘Alteration of steroidogenesis in boys with autism spectrum disorders’

Benedikt Andreas Gasser1, Johann Kurz2, Bernhard Dick3 and Markus Georg Mohaupt4

Dear Editor,

Janšáková et al. published a study in Translational Psychiatry that indicated that steroidogenesis in boys (average age 4.4 ± 1.1 years) with autism spectrum disorders differed from that in healthy controls1. The study involved comprehensive GC-MS analyses of blood samples from boys with autism and showed alterations of steroid hormones, especially higher androgen levels before puberty in boys with autism than in healthy controls. Janšáková et al. referred to our work in contrast to their findings in the discussion section and mentioned higher concentrations of unconjugated steroids, including most measured androstanes such as androsterone, etiocholanolone, androstenediol, 11β-hydroxyandrostosterone, 11β-hydroxyetiocholanolone, dehydroepiandrosterone, 5-androstan-3β and 17β-diol, in the urine during puberty in boys with autism than in controls5. This fact was explained by Janšáková et al. by precocious adrenarche leading to premature puberty, which has been described even in individuals with autism3,4. In summary, lower sulfated androstanes were reported by Janšáková et al. in boys (average age 4.4 years) with autism before puberty than in our sample of boys (average age 15.3 ± 2.9 years for Asperger and 13.6 ± 3.6 years for Kanner’s syndrome) with autism during puberty. Thus, the relation to the onset of puberty may be a key factor explaining the different results. Indeed, we believe that differences in the findings result from the lower average age and, consequently, pubertal status. In fact, human steroidogenesis is strongly age dependent, particularly in children and pubescents, supporting the relevance on this argument. However, additional factors might contribute to differences in the findings such as (i) measurement of steroid hormones in plasma versus urine, (ii) the backdoor pathway of androgen synthesis and (iii) altered activity of enzymatic pathways.

Steroid hormone measurement in plasma versus urine

Janšáková et al. performed measurements from plasma in contrast to our sample with urine analysis. We believe that the UGT polymorphism is especially relevant5–9. We mainly measured products of phase II metabolism in our urine samples. Consequently, it is important to understand that endocrine disruptors, UGT polymorphisms, drugs, alcohol and dietary supplements may affect the glucuronidation of steroid hormones, cofounding the results and consequently complicating direct comparisons5–9. We were also able to identify increased levels of androgens, such as testosterone, androstenediol, 11β-hydroxyandrostosterone and the mineralocorticoid tetrahydroaldosterone, in the urine of pubertal autistic girls. Although the results were less pronounced than in boys, this is in line with the statement of Janšáková et al. that there is involvement of all three layers of the adrenal gland (zona glomerulosa, zona fasciculata and zona reticularis) and highlights the relevance of this organ10.

Backdoor pathway of androgen synthesis

When focusing on biochemical pathways of androgen synthesis, two major pathways should be considered: the classic and backdoor pathways11–14. In short, human steroidogenic enzymes efficiently catalyse all the required steps in a route to dihydrotestosterone that does not involve the testosterone intermediate, called the backdoor pathway of androgen synthesis15. The backdoor pathway of androgen synthesis provides a faster route to dihydrotestosterone16. It has been reported that backdoor pathways play an
important role in human hyperandrogenic disorders such as 21-hydroxylase deficiency, Fragile-X-syndrome or altered sexual development17–22 but also in physiological states such as mini puberty (a short increase in androgen levels in the first year of life)15,21–23. O’Shaugnessy et al. showed that the main androgen of the backdoor pathway is androsterone22. In contrast, eticholanolone is mainly present in the classic pathway of androgen synthesis, which means that increased ratios of androsterone-to-eticholanolone may explain the potential activity of the backdoor pathway15,23–25. Consequently, androsterone-to-eticholanolone ratios are used as indicators for backdoor pathway activity in androgen synthesis, and alterations are associated with autism15–21,26–28. Thus, an increase in androsterone-to-eticholanolone ratios should be indicative of increased activity of this pathway22,28. However, in our sample, in contrast to the analyses of Janšáková et al., the metabolites androsterone and eticholanolone showed approximately twofold higher concentrations than those in controls, and as a consequence, the androsterone-to-eticholanolone ratios were not increased22,28. Based on these analyses, there is no evidence for higher or lower backdoor pathway activity in androgen synthesis28. These results are in contrast to those of Janšáková et al., suggesting lower activity of the backdoor pathway, as both metabolites were present at lower levels in boys with autism. Therefore, there is still uncertainty concerning the involvement of the backdoor pathway of androgen synthesis in girls and boys with autism, and explanations remain speculative, particularly because we have data from only relatively small samples.

**Alterations of enzymatic pathways**

Enzymatic pathways were differentially altered in the two samples analysed. For example, a 21-hydroxylase deficiency is not clearly detectable in our analyses, yet alterations in 17-hydroxylase, 11-hydroxylase and 11-β hydroxysteroid dehydrogenase were present in our sample. When focusing on 11-β hydroxysteroid dehydrogenase activity, interestingly, cortisol and cortisone metabolites were almost similarly changed in both samples, implying reduced 11-β hydroxysteroid dehydrogenase activity, which is in line with the previously reported role of hypercortisolism in an original description of autism29,30. In conclusion, analyses of steroid hormones by Janšáková et al., by our group and by others imply that there are higher concentrations of androgens in boys and girls with autism1–3,10,31–33. One main factor is the condition of the adrenal gland before and after puberty. One general premise might be that the zona reticularis is mainly active after puberty34. This would explain the higher activity of the CYP17A hydroxylase step in the absence of the lyase step in young children1,34. Once the zona reticularis of the adrenal gland is activated, increased production of adrenal androgens can be detected through increased lyase activity1,34. This premise would be supported by findings indicating that even children at the age of 6 still have negligible activity of the adrenal zona reticularis34. This premise would be in line with the general finding of higher androgens in boys and girls with autism after puberty2,21,12. It is tempting to speculate about the role of the gonads, and the focus should be on a dysregulated adrenal gland in autism2,21. Furthermore, it seems that more than a hormonal change underlies the pathology of autism1. Altered hormonal profiles might be a result of altered gene expression of hormone-associated or -related genes1,35–37. For this reason, the steroid hormonal profile and genetic background should be further investigated1,35–37.

In summary, despite notable differences between studies (measurements in urine in our study versus in plasma in the study by Janšáková et al., as well as different ages of the samples), higher levels of steroid hormones are very likely to suggest in autism. Therefore, the cholesterol hypothesis of autism of Gillberg et al. is in line with the findings of the two studies36. However, an encompassing view of all steroid hormone interactions is difficult. It seems that steroid hormone cascades act as complex networks with multiple entries and parallel signalling pathways in which hormones affect each other and are regulated by feedback and feed-forward mechanisms36. Furthermore, we do not know all players in these steroid networks, and these networks are not hierarchically or logically structured. The apparent complexity makes intuitive or mathematical prognosis impossible at the moment, easy applicable diagnostic markers are out of view39 and further research is warranted to deepen our understanding of alterations in steroid hormones in children with autism.

**Acknowledgements**

We thank all families and their children who participated in this study for their commitment to supporting our efforts to resolve the enigma of autism spectrum disease.

**Author details**

1DSBG, University of Basel, 4052 Basel, Switzerland. 2Intersci Research Association, Karl Morre Gasse 10, 8430 Leibnitz, Austria. 3Department of Clinical Research, University of Bern, 3010 Bern, Switzerland. *Teaching Hospital Internal Medicine, Lindehofgruppe, 3006 Bern, Switzerland

**Conflict of interest**

The authors declare no competing interests.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 October 2020 Revised: 16 April 2021 Accepted: 21 April 2021
Published online: 10 May 2021

**References**

1. Janšáková, K. et al. Alteration of the steroidogenesis in boys with autism spectrum disorders. Transl. Psychiatry 10, 340 (2020).
2. Gasser, B. A., Kurz, J., Dick, B. & Mohaupt, M. G. Steroid metabolites support evidence of autism. *Behav. Sci.* 9, 52 (2019).

3. Majewska, M. D. et al. Marked elevation of adrenal steroids, especially androgens, in saliva of prepubertal autistic children. *Eur. Child Adolesc. Psychiatry* 23, 485–498 (2014).

4. Winter, S., Durand, A. & Brauner, R. Precocious and early central puberty in children with pre-existing medical conditions: a single center study. *Pediatr. Dev. Pediatr.* 7, 35 (2019).

5. Ackermann, D. et al. Reference intervals for the urinary steroid metabolome: the impact of sex, age, day and night time on human adult steroidogenesis. *PLoS ONE* 14, e0214549 (2019).

6. Park, J. et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. *Cancer Epidemiol. Biomark.* 15, 1473–1478 (2006).

7. Jakobsson, J. et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. *J. Clin. Endocrinol. Metab.* 91, 687–693 (2006).

8. de Leon, J. Glucuronidation enzymes, genes and psychiatry. *Int J. Neuropsychopharmacol.* 6, 57–72 (2003).

9. Stein, T. P., Schluter, M. D., Steer, R. A. & Ming, X. Autism and phthalate metabolite glucuronidation. *J. Autism Dev. Disord.* 43, 2677–2685 (2013).

10. Gasser, B. A., Kurz, J., Dick, B. & Mohaupt, M. G. Are Steroid Hormones Dysregulated in Autistic Girls? *Diseases*. 8, 6, https://doi.org/10.3390/diseases8010006 (2020).

11. Dhayat, N. A. et al. Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from the urinary steroid metabolome. *Steroid. Biochem. Mol. Biol.* 165, 312–322 (2017).

12. Flück, C. E. et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. *Am. J. Hum. Genet.* 89, 201–218 (2011).

13. Fukami, M., Homma, K., Hasegawa, T. & Ogata, T. Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. *Dev. Dyn.* 242, 320–329 (2012).

14. Aucius, R. J. The backdoor pathway to dihydrotestosterone. *Trends Endocrinol. Metab.* 15, 432–438 (2004).

15. Kamrath, C., Hochberg, Z., Hartmann, M. F., Remer, T. & Wudy, S. A. Increased activation of the alternative ‘backdoor’ pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. *J. Clin. Endocrinol. Metab.* 93, E367–E375 (2012).

16. Margolese, M. S. & Janiger, O. Androsterone/etiocholanolone ratios in male homosexuals. *Br. Med. J.* 3, 2007–210 (1973).

17. Miller, W. L. & Aucius, R. J. The molecular biology, biochemistry and physiology of human steroidogenesis and its disorders. *Endocr. Rev.* 32, 81–151 (2011).

18. Oph Hof, J., Johnstone, J. & Venter, P. A. Hormone studies in patients with the Martin-Bell syndrome. *S. Afr. Med. J.* 63, 65 (1983).

19. Venter, P. A., Oph Hof, J. & Coetsee, D. J. The Martin-Bell syndrome in South Africa. *Am. J. Med. Genet.* 23, 597–610 (1986).

20. Evans, R. B. Physical and biochemical characteristics of homosexual men. *J. Consulting. Clin. Psychol.* 39, 140 (1972).

21. Miller, W. L. & Aucius, R. J. The “backdoor pathway” of androgen synthesis in human male sexual development. *PLoS Biol.* 17, e3001019 (2019).

22. O’Shaughnessy, P. J. et al. Alternative (backdoor) androgen production and masculinization in the human fetus. *PLoS Biol.* 17, e3000002 (2019).

23. Ahl, W. et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. *Lancet* 3128–3135 (2004).

24. Johnsen, S. G. Abnormal urinary androsterone/etiocholanolone ratio in hypothalamic disturbances in man. *Eur. J. Endocrinol.* 57, 959–614 (1968).

25. Homma, K. et al. Urine steroid hormone profile analysis in cytomegaly P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. *J. Clin. Endocrinol. Metab.* 91, 2632–2649 (2006).

26. Brown, W. T. et al. Association of fragile X syndrome with autism. *Lancet* 1, 100 (1982).

27. Yu, T. W. & Berry-Kravis, E. Autism and fragile X syndrome. *Semin. Neurol.* 34, 258–265 (2014).

28. Gasser, B. A., Kurz, J., Dick, B. & Mohaupt, M. G. Is there a dysregulation of backdoor pathway in autism. *Glob. J. Med. Res.* 20, 9–14 (2020).

29. Gasser, B. A. The case of hellmuth in the autistic psychopath – suffering from Cushing syndrome? *Glob. J. Intellect. Dev. Disabil.* 4, 555643 (2018).

30. Gasser, B. Autistic Disorders – Was Endocrine Involvement Forecasted?. *Glob. J. Intellect. Dev. Disabil.* 4, 2018.

31. El-Baz, F., Hamza, R. T., Ayad, M. S. & Mahmoud, N. H. Hyperandrogeinemia in male autistic children and adolescents: relation to disease severity. *Int. J. Adolesc. Med. Heal.* 26, 79–84 (2014).

32. Ruta, L., Ingudomnukul, E., Taylor, K., Chakrabarti, B. & Baron-Cohen, S. Increased serum androstenedione in adults with autism spectrum conditions. *Psychoneuroendocrinology* 36, 1154–1163 (2011).

33. Knickmeyer, R., Baron-Cohen, S., Wheelwright, S. & Knickmeyer, R. Elevated rates of testosterone-related disorders in women with autism spectrum conditions. *Horm. Behav.* 51, 597–604 (2007).

34. Rege, J. & Rainey, W. E. The steroid metabolite of adrenarche. *J. Endocrinol.* 214, 133–143 (2012).

35. Hu, V. W., Sarachana, T., Sherrard, R. M. & Kocher, K. M. Investigation of sex differences in the expression of RORA and its transcriptional targets in the brain as a potential contributor to the sex bias in autism. *Mol. Autism* 6, 7 (2015).

36. Sarachana, T., Xu, M., Wu, R. C. & Hu, V. W. Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. *PLoS ONE* 6, e17116 (2011).

37. Sarachana, T. & Hu, V. W. Differential recruitment of coregulators to the RORA promoter adds another layer of complexity to gene (dys) regulation by sex hormones in autism. *Mol. Autism* 4, 39 (2013).

38. Gilberg, C. et al. The role of cholesterol metabolism and various steroid abnormalities in autism spectrum disorders: a hypothesis paper. *Autism Res.* 10, 1022–1044 (2017).

39. Gasser, B., Kurz, K. & Mohaupt, M. Testosterone/Epistosterone Ratios—Further Hints to Explain Hyperandrogeinemia in Children with Autism. *Diseases* 9, 13 (2021).